The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma

The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma

The study on the value of PET imaging targeting granzyme B in predicting the efficacy and prognosis of T-NK cell lymphoma.

The investigators will number all participants, create a medical record file, and record their basic information (gender, age) as well as contact information and medical history information. All participants will undergo 68Ga-grazytracer PET at baseline and after one course of immunotherapy.

Inclusion Criteria:

1. Age > 18 years, regardless of gender.
2. Histopathologically confirmed diagnosis of T-NK cell lymphoma.
3. Newly diagnosed and untreated patients or refractory/relapsed patients preparing to undergo immunotherapy.
4. Availability of complete clinicopathological and follow-up data.
5. Signed and dated informed consent form.

Exclusion Criteria:

1. Patients who have previously received anti-tumor therapy.
2. Patients with a history of other malignancies.
3. Incomplete clinical information or imaging data.
4. Concurrent other malignant tumors.
5. Patients with severe medical conditions deemed unsuitable for participation in this clinical study by the investigator, such as severe cardiopulmonary insufficiency or severe hepatic and renal dysfunction.
6. Poor compliance.